Mario E Lacouture

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer
    Mario E Lacouture
    Northwestern University, Chicago, IL, USA
    J Clin Oncol 28:1351-7. 2010
  2. doi request reprint A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
    Mario E Lacouture
    Dermatology Service, Rockefeller Outpatient Pavilion, Memorial Sloan Kettering 53rd Street, 160 East 53rd Street, New York, NY 10022, USA
    Support Care Cancer 18:509-22. 2010
  3. pmc Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
    Mario E Lacouture
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
    Support Care Cancer 19:1079-95. 2011
  4. ncbi request reprint Ipilimumab in patients with cancer and the management of dermatologic adverse events
    Mario E Lacouture
    Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York Electronic address
    J Am Acad Dermatol 71:161-9. 2014
  5. ncbi request reprint Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma
    Mario E Lacouture
    Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Semin Oncol 41:S1-S14. 2014
  6. pmc Skin care management in cancer patients: an evaluation of quality of life and tolerability
    Ann Cameron Haley
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Support Care Cancer 19:545-54. 2011
  7. pmc Analysis of dermatologic events in vemurafenib-treated patients with melanoma
    Mario E Lacouture
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Oncologist 18:314-22. 2013
  8. doi request reprint Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
    Mario E Lacouture
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Expert Rev Anticancer Ther 13:721-8. 2013
  9. doi request reprint Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib
    Mario E Lacouture
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Oncologist 13:1001-11. 2008
  10. ncbi request reprint Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic
    Alyx C Rosen
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd St, New York, NY 10022, USA
    Am J Clin Dermatol 14:327-33. 2013

Detail Information

Publications64

  1. doi request reprint Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer
    Mario E Lacouture
    Northwestern University, Chicago, IL, USA
    J Clin Oncol 28:1351-7. 2010
    ..This is the first study designed to examine differences between pre-emptive and reactive skin treatment for specific skin toxicities in patients with mCRC for any EGFR inhibitor...
  2. doi request reprint A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
    Mario E Lacouture
    Dermatology Service, Rockefeller Outpatient Pavilion, Memorial Sloan Kettering 53rd Street, 160 East 53rd Street, New York, NY 10022, USA
    Support Care Cancer 18:509-22. 2010
    ..We believe a class-specific grading scale is needed to help standardize assessment and improve reporting of EGFRI-associated dermatologic AEs...
  3. pmc Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
    Mario E Lacouture
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
    Support Care Cancer 19:1079-95. 2011
    ..The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities...
  4. ncbi request reprint Ipilimumab in patients with cancer and the management of dermatologic adverse events
    Mario E Lacouture
    Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York Electronic address
    J Am Acad Dermatol 71:161-9. 2014
    ..Adherence to guidelines is necessary to maintain quality of life, ensure consistent dosing, and obtain the best possible clinical outcome. ..
  5. ncbi request reprint Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma
    Mario E Lacouture
    Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Semin Oncol 41:S1-S14. 2014
    ..The addition of skin care strategies to the NovoTTF-100A System use will maximize adherence to therapy while maintaining quality of life, all of which contribute to the therapeutic benefit of NovoTTF Therapy in rGB. ..
  6. pmc Skin care management in cancer patients: an evaluation of quality of life and tolerability
    Ann Cameron Haley
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Support Care Cancer 19:545-54. 2011
    ..The objective of this study is to evaluate quality of life (QoL) and tolerability of three articles specifically developed for cancer skin care management (skin moisturizer, face moisturizer, and face wash)...
  7. pmc Analysis of dermatologic events in vemurafenib-treated patients with melanoma
    Mario E Lacouture
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Oncologist 18:314-22. 2013
    ..This report by the Vemurafenib Dermatology Working Group presents the characteristics of dermatologic adverse events (AEs) that occur in vemurafenib-treated patients, including cutaneous squamous cell carcinoma (cuSCC)...
  8. doi request reprint Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
    Mario E Lacouture
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Expert Rev Anticancer Ther 13:721-8. 2013
    ..This article summarizes current data on the dermatologic AEs associated with afatinib treatment across the clinical trial program, and provides strategies for their effective management...
  9. doi request reprint Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib
    Mario E Lacouture
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Oncologist 13:1001-11. 2008
    ..Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy...
  10. ncbi request reprint Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic
    Alyx C Rosen
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd St, New York, NY 10022, USA
    Am J Clin Dermatol 14:327-33. 2013
    ..Although the frequency and severity of these events have been described, their effects on health-related quality of life (QoL) remain poorly understood, and the ones having a greater impact have not been ascertained...
  11. ncbi request reprint The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life
    Beatrice Nardone
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    J Drugs Dermatol 11:e61-5. 2012
    ..The aim of this study is to evaluate the impact of HFSR associated with these multikinase inhibitors on patient health-related quality of life (HRQOL)...
  12. doi request reprint Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis
    David Chu
    Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, NY 11794 9447, USA
    Clin Genitourin Cancer 7:11-9. 2009
    ..86; 95% CI, 3.1-31.31; P < .001) in comparison with controls. There is a significant risk of developing HFSR in patients with cancer receiving sunitinib. Adequate monitoring and intervention are recommended for reducing the toxicity...
  13. doi request reprint Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis
    David Chu
    Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
    Acta Oncol 47:176-86. 2008
    ..This study was conducted to determine the risk of developing HFSR among patients receiving sorafenib...
  14. ncbi request reprint Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis
    Alyx C Rosen
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 East 53rd Street, New York, New York 10022, USA
    J Clin Endocrinol Metab 97:1125-33. 2012
    ..Therefore, we conducted a systematic review and meta-analysis of the literature to determine the incidence and risk of developing a rash...
  15. doi request reprint Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life
    Smita S Joshi
    Skin and Eye Reactions to Inhibitors of Epidermal Growth Factor Receptor and Kinase SERIES Clinic and Cancer Skin Care Program, Department of Dermatology and Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cancer 116:3916-23. 2010
    ..By using a dermatology-specific questionnaire, the authors examined the effect of these toxicities on QoL...
  16. ncbi request reprint Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis
    Yuxia Jia
    Division of Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York 11794 9447, USA
    J Support Oncol 7:211-7. 2009
    ..72 (95% CI: 3.56-6.20) for erlotinib alone and 2.34 (95% CI: 1.64-3.34) for the erlotinib combination. In conclusion, erlotinib is associated with substantial skin toxicity that may be modified by chemotherapy...
  17. ncbi request reprint Dermoscopic findings in cutaneous metastases
    Karen A Chernoff
    Department of Dermatology, Weill Cornell Medical College, New York, New York
    JAMA Dermatol 150:429-33. 2014
    ..These findings support the use of dermoscopy in the evaluation of suspected skin metastases or in the assessment of lesions of unknown origin in patients with cancer. ..
  18. ncbi request reprint Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients
    Beatrice Nardone
    Department of Dermatology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Clin Cancer Res 16:4452-60. 2010
    ....
  19. doi request reprint Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis
    Viswanath Reddy Belum
    Dermatology Service, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 E 53rd St, New York, NY 10022, USA
    Invest New Drugs 31:1078-86. 2013
    ..The incidence and risk of HFSR with regorafenib have not been systematically investigated...
  20. doi request reprint Dermatological adverse events from BRAF inhibitors: a growing problem
    Viswanath Reddy Belum
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 East 53rd St, New York, NY, 10022, USA
    Curr Oncol Rep 15:249-59. 2013
    ..In this manuscript, we provide an overview of the emerging scientific literature on dermatological adverse events arising out of BRAF inhibition...
  21. doi request reprint The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis
    Kira Minkis
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    J Am Acad Dermatol 69:e121-8. 2013
    ..Dermatologic adverse events such as rash, pruritus, and vitiligo have been reported in trials, with varying incidences. The overall incidence and risk of rash to ipilimumab is unknown...
  22. ncbi request reprint Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis
    Beatrice Nardone
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Clin Lymphoma Myeloma Leuk 13:424-9. 2013
    ..Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes. The incidence and risk of rash has been inconsistently reported...
  23. doi request reprint Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4
    Alyssa Fischer
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Dermatol Ther 26:135-48. 2013
    ....
  24. doi request reprint The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis
    Yevgeniy Balagula
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
    Invest New Drugs 30:1773-81. 2012
    ..1-6.2, p < 0.001). Despite sharing the same spectrum of target receptors with sorafenib and sunitinib, pazopanib is associated with an unexpectedly low risk of HFSR. Further investigations are needed to elucidate HFSR pathogenesis...
  25. doi request reprint The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)
    Lynne I Wagner
    Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Support Care Cancer 21:1033-41. 2013
    ..The Functional Assessment of Cancer Therapy (FACT)-EGFRI was developed to measure HRQL among patients receiving EGFRIs...
  26. doi request reprint Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
    Yevgeniy Balagula
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Dermatol 50:129-46. 2011
    ..This review will describe the clinical presentation, histopathology, underlying mechanisms, and management options, emphasizing evidence-based approaches...
  27. doi request reprint Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis
    Xiao Su
    Department of Medicine, AtlantiCare Regional Medical Center, Atlantic City, NJ, USA
    Oncology 77:124-33. 2009
    ..Its efficacy in the treatment of other cancers is also undergoing extensive investigation. We performed a systemic review and meta-analysis of published clinical trials to quantify the overall incidence and risk of severe skin rash...
  28. doi request reprint Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents
    Judy H Borovicka
    Department of Dermatology, SERIES Clinic, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Arch Dermatol 147:1403-9. 2011
    ..To report the financial impact of diagnosing and treating the dermatologic toxicities (dTs) that develop in patients receiving targeted anticancer therapies...
  29. ncbi request reprint Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer
    Mario E Lacouture
    Cancer Skin Care Program and SERIES Clinic, Department of Dermatology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Ill 60611 2941, USA
    Cancer Nurs 30:S17-26. 2007
    ..Effective management of these adverse effects may lessen the chance of suboptimal therapy and requires an understanding of the underlying pathophysiology, as well as knowledge of useful strategies for alleviating these effects...
  30. ncbi request reprint Clinical management of EGFRI dermatologic toxicities: US perspective
    Mario E Lacouture
    Department of Dermatology, Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Oncology (Williston Park) 21:17-21. 2007
    ..Two dermatologists who treat high numbers of patients affected by these EGFRI-induced cutaneous side effects submit their recommendations for management...
  31. pmc Life-threatening dermatologic adverse events in oncology
    Alyx C Rosen
    aDepartment of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York bDepartment of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of New Mexico cVeterans Affairs Cooperative Studies Program, Albuquerque, New Mexico dDepartment of Dermatology eRobert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois fDepartment of Internal Medicine, Division of Dermatology, Washington University School of Medicine, St Louis, Missouri, USA
    Anticancer Drugs 25:225-34. 2014
    ..Proactive pharmacovigilance to detect and define safety signals serves to aid oncology practitioners in the recognition of possible, yet uncommon, serious, and/or life-threatening skin reactions. ..
  32. ncbi request reprint The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors
    Mario E Lacouture
    Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    J Support Oncol 4:236-8. 2006
  33. doi request reprint Treatment of multiple keratoacanthomas with erlotinib
    David C Reid
    Department of Dermatology, Feinberg School of Medicine, Northwestern University, 676 N St Clair St, Suite 1600, Chicago, IL 60611, USA
    Int J Clin Oncol 15:413-5. 2010
    ..This is the first report of multiple keratoacanthomas responding to therapy with an EGFR tyrosine kinase inhibitor, and it supports an emerging role for the use of EGFR inhibitors in the management of cutaneous malignancies...
  34. ncbi request reprint Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis
    Courtney J Ensslin
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    J Am Acad Dermatol 69:708-20. 2013
    ..Pruritus has been anecdotally described in association with targeted cancer therapies. The risk of pruritus has not been systematically ascertained...
  35. ncbi request reprint Dermatologic toxicities of targeted anticancer therapies
    Yevgeniy Balagula
    Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    J Support Oncol 8:149-61. 2010
    ....
  36. doi request reprint Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors
    Peggy A Wu
    Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Oncol 23:343-51. 2011
    ..These dermatologic toxicities have previously led to reduction or cessation of therapy and recently have been shown to decrease patients' quality of life...
  37. ncbi request reprint Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib
    Minnelly Luu
    Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Photodermatol Photoimmunol Photomed 23:42-5. 2007
    ....
  38. doi request reprint Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
    Yevgeniy Balagula
    Dermatology Service, Department of Medicine, Rockefeller Outpatient Pavilion, Memorial Sloan Kettering Cancer Center, 160 East 53rd Street, New York, NY 10022, USA
    Invest New Drugs 29:1114-21. 2011
    ..Similarly, their management may present a challenge in clinical trials. We reviewed the clinical presentation, evolution and management of dermatologic toxicities associated with selumetinib...
  39. pmc Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma
    Federica Catalanotti
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2257-64. 2013
    ..Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated...
  40. ncbi request reprint Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results
    Susan L Boone
    Department of Dermatology, SERIES Clinic, Northwestern University s Feinberg School of Medicine, Chicago, Ill 60611, USA
    Oncology 72:152-9. 2007
    ..The survey results support that attentive cutaneous care is important in patients treated with EGFR inhibitors, and that proactive/combined interventions may enhance quality of life and optimize consistent drug administration...
  41. doi request reprint Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management
    Viswanath Reddy Belum
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 E 53rd St, New York, NY, 10022, USA
    Curr Treat Options Oncol 14:389-404. 2013
    ..Lastly, further research at the molecular and cellular level may assist in the elucidation of the mechanisms underlying these AEs and their clinical correlates, paving way for the design of effective therapies in this subset of patients...
  42. doi request reprint Skinflammation and drug toxicity--a delicate balance
    Mario E Lacouture
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    Sci Transl Med 5:199fs33. 2013
    ..and Lichtenberger et al., this issue). ..
  43. ncbi request reprint Blackberry-induced hand-foot skin reaction to sunitinib
    Susan L Boone
    Department of Dermatology, Northwestern University s Feinberg School of Medicine, Chicago, IL 60611, USA
    Invest New Drugs 27:389-90. 2009
    ....
  44. doi request reprint The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
    Alyssa Fischer
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228 160 E 53rd St, New York, NY, USA
    Invest New Drugs 31:787-97. 2013
    ..These findings underscore the importance of supportive dermatologic care in patients treated with axitinib, in order to maintain quality of life, adherence, and persistence to therapy...
  45. doi request reprint The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis
    Benjamin C Garden
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Am Acad Dermatol 67:400-8. 2012
    ..The overall incidence and risk of nail changes associated with the use of epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature...
  46. doi request reprint Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors
    Yevgeniy Balagula
    Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    Cancer 118:5078-83. 2012
    ..Inhibitors of mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus, have been associated with a high rate of skin eruptions, but their clinical and histopathologic characteristics have not been explored...
  47. ncbi request reprint Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy
    R E Eilers
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611 2941, USA
    J Natl Cancer Inst 102:47-53. 2010
    ..We examined the prevalence of infections that complicate dermatologic toxic effects of EGFRIs...
  48. doi request reprint Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials
    Kimberly A Bauer
    Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Clin Colorectal Cancer 7:309-14. 2008
    ..To improve patient counseling and prophylactic antitoxicity interventions, implementation of standards for reporting of dADRs is critical...
  49. doi request reprint Unanticipated toxicities from anticancer therapies: survivors' perspectives
    Mona Gandhi
    Department of Dermatology, Northwestern University s Feinberg School of Medicine, 676 N St Clair St, Suite 1600, Chicago, IL 60611, USA
    Support Care Cancer 18:1461-8. 2010
    ..These untoward events have not been examined from the survivors' perspective...
  50. pmc Alopecia with endocrine therapies in patients with cancer
    Vishal Saggar
    School of Medicine, New York University Langone Medical Center, New York, New York, USA
    Oncologist 18:1126-34. 2013
    ..Adherence to these therapies is suboptimal, in part because of toxicities. We performed a systematic analysis of the literature to ascertain the incidence and risk for alopecia in patients receiving endocrine therapies...
  51. ncbi request reprint Dermatologic issues in adult survivors of childhood cancer
    Karen E Kinahan
    Department of General Internal Medicine, Northwestern University, Chicago, IL, USA
    J Cancer Surviv 3:158-63. 2009
    ..Common late effects experienced by childhood cancer survivors include: thyroid disturbances, pulmonary compromise, heart failure, and secondary neoplasms. Dermatologic issues have been largely unexplored...
  52. ncbi request reprint Mechanisms of cutaneous toxicities to EGFR inhibitors
    Mario E Lacouture
    SERIES Clinic and Cancer Skin Care Program, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Suite 1600, Chicago, Illinois 60611, USA
    Nat Rev Cancer 6:803-12. 2006
    ..There is an urgent need for an improved understanding of these toxicities to develop adequate staging systems and mechanistically driven therapies, and to ensure quality of life and consistent antineoplastic therapy...
  53. doi request reprint Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review
    Durga S Borkar
    Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Support Care Cancer 21:1167-74. 2013
    ..The aim of this study is to describe common ocular adverse effects associated with EGFR inhibitor treatment, outline successful management options, and provide data on intermediate-term follow-up of these patients...
  54. ncbi request reprint Non-rash skin toxicities associated with novel targeted therapies
    Mario E Lacouture
    Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 48201, USA
    Clin Lung Cancer 8:S36-42. 2006
    ..This review discusses several non-rash dermatologic toxicities observed with targeted therapeutic agents and guidelines for their diagnosis and treatment...
  55. ncbi request reprint Dermatologic challenges in cancer patients and survivors
    Rania Agha
    Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Oncology (Williston Park) 21:1462-72; discussion 1473, 1476, 1481 passim. 2007
    ..This review provides a basis for the understanding of dermatologic events in the oncology setting, in order to promote attentive care to cutaneous health in cancer patients and survivors...
  56. ncbi request reprint The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies
    Yevgeniy Balagula
    Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    J Am Acad Dermatol 65:624-35. 2011
    ....
  57. ncbi request reprint Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae
    Lynne I Wagner
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Northwestern University, Feinberg Medical School, Chicago, IL 60611, USA
    Oncology (Williston Park) 21:34-6. 2007
    ..Cognitive behavioral strategies may also be useful in helping patients manage anxiety and depression associated with any changes in their social function caused by skin rash, as well as distress associated with having a cancer diagnosis...
  58. ncbi request reprint Dermatologic infections in cancer patients
    Mona Gandhi
    Division of Dermatology, John H Stroger, Jr Hospital of Cook County, 1900 W Polk Street, Administration Building, Room 519, Chicago, IL, 60612, USA
    Cancer Treat Res 161:299-317. 2014
    ..This chapter delineates dermatologic infections that are unique to cancer patients as a result of their underlying malignancies and associated comorbidities as well as those resulting from antineoplastic therapies. ..
  59. doi request reprint Skin toxicity of targeted cancer agents: mechanisms and intervention
    Viswanath Reddy Belum
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 248, 160 East 53rd Street, New York, NY 10022, USA
    Future Oncol 9:1161-70. 2013
    ..Emergent insights into the pathomechanisms involved and the use of this knowledge base to alleviate cutaneous adverse events are discussed. ..
  60. ncbi request reprint The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies
    Lavanya Kondapalli
    Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA
    J Am Acad Dermatol 53:291-302. 2005
    ..These drugs will have important implications in clinical dermatology, based on their expected frequent use in the treatment of dermatologic malignancies, and their associated cutaneous side effects...
  61. pmc Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
    Michael L Maitland
    University of Chicago, Section of Hematology Oncology, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    BMC Cancer 14:5. 2014
    ..In a phase II trial that was closed to accrual because of changes in clinical practice we examined the relationships among candidate biomarkers, quantitative changes in tumor size, progression-free and overall survival...
  62. ncbi request reprint KSHV/HHV8-associated primary cutaneous plasmablastic lymphoma in a patient with Castleman's disease and Kaposi's sarcoma
    Wenhua Liu
    Department of Pathology, University of Chicago Hospitals, Chicago, Illinois, USA
    J Cutan Pathol 33:46-51. 2006
    ....
  63. pmc Characteristics of oral mucosal events related to bevacizumab treatment
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Oncologist 17:274-8. 2012
    ..We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab...
  64. ncbi request reprint Hand-foot and stump syndrome to sorafenib
    Susan E Lai
    Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    J Clin Oncol 25:341-3. 2007